Pr ecis: These findings suggest a rationale for personalized treatment of certain leukemia patients with ALK kinase inhibitors, with immediate implications for clinical evaluation.
Pr ecis: In combination with a T-cell microinfusion into the brain, a novel bispecific antibody that delivers T cells to glioma stem-like cells mediates strong antitumor effects.
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Full-Length Semaphorin-3C Is an Inhibitor of Tumor Lymphangiogenesis and Metastasis
Yelena Mumblat, Ofra Kessler, Neta Ilan, and Gera Neufeld Pr ecis: An antibody-based strategy to block the development of new lymph vessels into tumors, as well as the metastasis of tumor cells into lymph nodes, suggests the antibody may offer generalized therapeutic potential to treat any solid tumor. Pr ecis: Patients who receive local radiotherapy can benefit from cotreatment with a neutralizing TGFb antibody, which appears to generate a personalized vaccination effect against the tumor, even in patients who do not respond to immune checkpoint blockade. Pr ecis: These findings offer a preclinical proof of principle for the use of an optimized nuclear-penetrating autoantibody against DNA as a targeted therapy for tumors with preexisting defects in homology-directed repair. Pr ecis: This mechanistic advance in understanding the invasive behavior of metastasis-initiating stem-like cells in prostate cancer, the first step in progression to untreatable disease, suggests a new targeted approach to eradicate this important tumor cell subpopulation.
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JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms
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FoxM1 Drives a Feed-Forward STAT3-Activation Signaling Loop That Promotes the Self-Renewal and Tumorigenicity of Glioblastoma Stem-like Cells Ai-hua Gong, Ping Wei, Sicong Zhang, Jun Yao, Ying Yuan, Ai-dong Zhou, Frederick F. Lang, Amy B. Heimberger, Ganesh Rao, and Suyun Huang Pr ecis: These findings define how the key glioma-driving growth factor PDGF-A is upregulated in glioma and define a transcriptional network required to maintain selfrenewal of stem-like cells in this deadly brain cancer.
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Vimentin-ERK Signaling Uncouples Slug Gene Regulatory Function 
ABOUT THE COVER
Some lupus autoantibodies penetrate into live cells, and the potential to use these cellpenetrating antibodies against cancer is an emerging concept. An optimized lupus anti-DNA antibody construct, 3E10 di-scFv, has now been shown to localize into cell nuclei and to selectively cause accumulation of DNA damage in and kill cancer cells with certain defects in DNA repair and therefore has potential in targeted cancer therapy. In this image the fluorescent signal demonstrates nuclear localization by the optimized lupus antibody construct in DLD1 colon cancer cells that were immunostained after treatment with 3E10 di-scFv. For details, see article by Noble and colleagues on page 2285. To request permission to re-use all or part of this article, contact the AACR Publications Department at
